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IMPORTANCE Sudden cardiac death (SCD) is the most common mode of death in childhood
hypertrophic cardiomyopathy (HCM), but there is no validated algorithm to identify those
at highest risk.
OBJECTIVE To develop and validate an SCD risk prediction model that provides individualized
risk estimates.
DESIGN, SETTING, AND PARTICIPANTS A prognostic model was developed from a
retrospective, multicenter, longitudinal cohort study of 1024 consecutively evaluated
patients aged 16 years or younger with HCM. The study was conducted from January 1, 1970,
to December 31, 2017.
EXPOSURES The model was developed using preselected predictor variables (unexplained
syncope, maximal left-ventricular wall thickness, left atrial diameter, left-ventricular outflow
tract gradient, and nonsustained ventricular tachycardia) identified from the literature and
internally validated using bootstrapping.
MAIN OUTCOMES AND MEASURES A composite outcome of SCD or an equivalent event
(aborted cardiac arrest, appropriate implantable cardioverter defibrillator therapy, or
sustained ventricular tachycardia associated with hemodynamic compromise).
RESULTS Of the 1024 patients included in the study, 699 were boys (68.3%); mean
(interquartile range [IQR]) age was 11 (7-14) years. Over a median follow-up of 5.3 years (IQR,
2.6-8.3; total patient years, 5984), 89 patients (8.7%) died suddenly or had an equivalent
event (annual event rate, 1.49; 95% CI, 1.15-1.92). The pediatric model was developed using
preselected variables to predict the risk of SCD. The model’s ability to predict risk at 5 years
was validated; the C statistic was 0.69 (95% CI, 0.66-0.72), and the calibration slope was
0.98 (95%, CI 0.59-1.38). For every 10 implantable cardioverter defibrillators implanted in
patients with 6% or more of a 5-year SCD risk, 1 patient may potentially be saved from SCD
at 5 years.
CONCLUSIONS AND RELEVANCE This new, validated risk stratification model for SCD in
childhood HCM may provide individualized estimates of risk at 5 years using readily obtained
clinical risk factors. External validation studies are required to demonstrate the accuracy of
this model's predictions in diverse patient populations.
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S udden cardiac death (SCD) is the most common modeof death outside of infancy in childhood hypertrophiccardiomyopathy (HCM),1,2 with higher annual rates com-
pared with those in adults with the disease.3 Current practice
guidelines recommend primary prevention implantable car-
dioverter defibrillators (ICDs) in children based on the pres-
ence of clinical risk factors for SCD extrapolated mostly from
observational adult studies,4,5 but this approach poorly dis-
criminates risk in both adult and pediatric populations.6,7 A
clinical risk tool (HCM Risk-SCD) that estimates the 5-year risk
of SCD was developed8 and validated in adults with HCM.9-12
The aim of this study was to develop a similar pediatric SCD
risk model using a large, international cohort and compare its
performance with the adult model.
Methods
Study Population
The study cohort consisted of patients aged 1 to 16 years with
HCM who were consecutively evaluated between January 1,
1970, and December 31, 2017, in 39 participating centers lo-
cated in 17 countries (the International Paediatric Hypertro-
phic Cardiomyopathy Consortium; eTable 1 in the Supple-
ment). A diagnosis of HCM was defined as a left-ventricular wall
thickness greater than 2 SDs above the body surface area–
corrected population mean (z score ≥2) that could not be ex-
plained solely by abnormal loading conditions or in accor-
dance with published criteria for familial disease.5 Patients with
prior ventricular fibrillation or sustained ventricular tachycar-
dia (VT), known inborn errors of metabolism or syndromic
causes of HCM (eg, RASopathy syndromes, Friedreich ataxia),
presentation under 1 year, or less than 1 month of follow-up
were excluded (eFigure 1 in the Supplement). The authors from
each participating center guaranteed the integrity of data from
their institution and had approval from a local ethics commit-
tee with waiver of informed consent.
Patient Assessment and Data Collection
Anonymized, noninvasive clinical data from a baseline evalu-
ation were collected retrospectively, including demographics,
cause of the disease, heart failure symptoms (New York Heart
Association [NYHA]/Ross functional classification13), pedigree
analysis, resting and ambulatory 12-lead electrocardiogram, and
2-dimensional Doppler and color transthoracic echocardio-
gram (from contemporaneously written reports). Patients had
planned clinical reviews every 6 to 18 months. Data were col-
lected independently at each participating center.
Clinical Outcomes
The primary study end point was a composite outcome of
SCD or an equivalent event (aborted cardiac arrest, appropriate
ICD therapy, or sustained VT associated with hemodynamic
compromise).8,11,14,15 Asinpreviousstudies,ICDtherapywascon-
sidered appropriate if the tachyarrhythmia was ventricular in
origin.11,16,17 Sudden cardiac death was defined as a witnessed
sudden death with or without documented cardiac failure, death
within 1 hour of new symptoms, or nocturnal deaths with no an-
tecedent history of worsening symptoms.18 Outcomes were
ascertained by the treating cardiologist at each center.
Selection of Predictor Variables
A systematic review of the literature was performed in De-
cember 201519 to identify SCD risk factors with sufficient evi-
dence to support their inclusion as predictor variables in the
risk model (eTable 2 in the Supplement). Clinical risk factors
were included as predictor variables if they had been exam-
ined in more than 2 published studies and independently as-
sociated with SCD in 2 or more univariable or multivariable sur-
vival analyses. Selection of predictor variables was not limited
to studies with multivariable analyses owing to the limited evi-
dence base available in pediatric HCM (all but 1 study in-
cluded in the meta-analysis was retrospective, the majority had
fewer than 150 participants, and most published studies used
only univariable analyses).19 Candidate predictors are de-
fined in Table 1. To account for somatic growth, maximal wall
thickness and left atrial diameter measurements are ex-
pressed as z scores (defined as the number of SDs above or be-
low the body surface area–corrected mean as a given measure-
ment’s mean).24 The largest published reference populations
for interventricular septal thickness22 and left atrial diameter23
were chosen following a review of the literature.
Statistical Analysis
Continuous variables are described as mean (SD) or median and
interquartile range (IQR) as appropriate. Because the model was
developed to predict 5-year SCD risk during childhood (age ≤16
years), the follow-up of patients was censored at age 22 years.
The follow-up time for all patients was thus calculated from
the date of their first evaluation to the date of reaching the
study end point, death from another cause, or the date of their
most recent evaluation prior to the end of the study period (De-
cember 2017 or age 22 years). Kaplan-Meier survival plots were
used to describe the failure times.
Handling of Missing Data
Patients with more than 50% of the preselected predictors
missing were excluded from model development. Logistic re-
gression was used to identify predictors of missingness. The
Key Points
Question Can sudden cardiac death risk in children with
hypertrophic cardiomyopathy be predicted?
Findings In this cohort study of 1024 consecutively evaluated
children (age 16 years), a prognostic model was developed using
preselected predictor variables identified from the literature. The
model’s ability to predict risk at 5 years was internally validated
using bootstrapping.
Meaning This new, validated risk stratification model for sudden
cardiac death risk in childhood hypertrophic cardiomyopathy may
provide individualized estimates of risk at 5 years using readily
obtained data on clinical risk factors; external validation studies
are required to demonstrate the accuracy of this model's
predictions in diverse patient populations.
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values for the missing predictors were imputed using mul-
tiple imputation techniques based on chained equations.25 The
imputation model included all predictors of missingness,
the outcome, all prespecified predictors of the risk model, and
the estimate of the cumulative hazard function.26 A total of 49
imputed data sets were generated, and estimates obtained from
the imputed data sets were combined using the Rubin rule.27
Development of the Pediatric Model
A minimum of 10 SCD or equivalent events are required per
coefficient in the model to estimate the regression coeffi-
cients with adequate precision.28 This means that 50 SCD
events would be required to allow estimation of the regres-
sion coefficients for the 5 preselected predictors with ad-
equate precision. Additional events would be required for in-
clusion of nonlinear terms associated with the continuous
predictors in the model.
All continuous predictors were centered around their mean
values, and univariable Cox proportional hazards regression
models were used to test the assumption of linearity with the
outcome for each continuous predictor. The final model was
developed using a Cox proportional hazards regression model
including all 5 preselected predictors and quadratic terms for
the continuous predictors where nonlinearity was found in the
univariable analysis. The proportional hazards assumption was
investigated using Schoenfeld residuals.29 A sensitivity analy-
sis was performed by including the predictors of missingness
in the final model. All regression models were fitted using ro-
bust SEs to account for clustering by center.30
The probability of SCD at t years for an individual patient
can be calculated using the following equation, derived from
the Cox proportional hazards regression model:
P̂SCD at t years = 1 – S0(t) exp(prognostic index),
where S0(t) is the average survival probability at time t and the
prognostic index is the sum of the products of the predictors
and their coefficients.
Bootstrapping was used to evaluate the performance of the
model since this is the most efficient validation procedure as
all aspects of the model development are validated.31 For this
purpose, 200 bootstrap samples were generated from each im-
puted data set and estimates were combined. Because the aim
of the model is to predict 5-year SCD risk, patients were cen-
sored at 5 years from their first evaluation. The calibration slope
was used to assess the degree of agreement between the ob-
served and predicted hazards of SCD (a value close to 1 sug-
gests good overall agreement).32 The C index (C-Uno33) was
used to measure how well the model discriminated between
high- and low-risk patients.34 A value of 1 indicates perfect dis-
crimination and a value of 0.5 indicates no discrimination. The
C index and calibration results presented are an average of the
bootstrapped samples. Graphic comparisons of the observed
and predicted risk of SCD at 5 years by risk groups (0%-<2%,
2%-<4%, 4%-<6%, and ≥6%) based on an imputed develop-
ment sample are provided.
The model development process is summarized in eFig-
ure 1 in the Supplement. Statistical analysis was performed
using Stata Statistical Software, release 14 (StataCorp LP).
Results
Baseline Clinical Characteristics
The study cohort comprised 1024 patients from 39 centers with
a median (IQR) age at baseline evaluation of 11 (7-14) years (eFig-
ure 2A in the Supplement); 699 patients (68.3%) were boys. A
family history of HCM was present in 534 of 1006 patients
(53.1%). Baseline clinical characteristics are described in Table 2
and eTable 3 in the Supplement.
Clinical Course and Outcomes During Follow-up
Over a follow-up period of 5984 patient-years (median, 5.3
years; IQR, 2.6-8.3), 77 patients (7.5%) underwent a myec-
tomy, 43 patients (4.2%) required a permanent pacemaker, and
Table 1. Candidate Predictor Definitions
Candidate Predictor Variable Definition Coding
NYHA/Ross functional class NYHA functional classification20/modified Ross heart failure classification
for children13 at baseline evaluation
Binary (NYHA/Ross 1 = 0,
NYHA/Ross ≥2 = 1)
Unexplained syncope Defined as a transient loss of consciousness with no identifiable cause
at or before first evaluation1,8,14,15
Binary (no = 0, yes = 1)
Nonsustained ventricular tachycardia ≥3 Consecutive ventricular beats at a rate of ≥120 beats/min lasting <30 s
on ambulatory ECG monitoring (minimum duration 24 h) at or before
first evaluation16,21
Binary (no = 0, yes = 1)
Maximal wall thickness z score Defined as the number of SDs from the population mean22; the 2-D measurement
of maximal wall thickness (millimeters) is at baseline evaluationa
Continuous (z score)
Left atrial diameter z score Defined as the number of SDs from the population mean23 the 2-D measurement
of maximal left-atrial diameter (millimeters) is at baseline evaluationb
Continuous (z score)
Maximal LV outflow tract gradient The maximum LV outflow tract gradient at rest or with Valsalva provocation using
continuous wave Doppler from the apical 3- or 5-chamber views17c
Continuous (mm Hg)
Abbreviations: 2-D, 2 dimensional; ECG, electrocardiogram; LV, left ventricular;
NYHA, New York Heart Association.
a Maximal wall thickness is the greatest thickness as measured by 2-D
echocardiography in the parasternal short-axis views of the left ventricle in 4
places at the level of the mitral valve and papillary muscles (anterior and
posterior septum, lateral and posterior wall) and in 2 places at the apical level
(anterior and posterior septum).5
b Left atrial diameter is determined by M mode or 2-D echocardiography in the
parasternal long-axis plane.
c Peak outflow tract gradient is determined using the modified Bernoulli
equation: gradient = 4V2, where V is the peak aortic outflow velocity.
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21 patients (2.1%) underwent cardiac transplantation. A total
of 267 patients (26.1%) received an ICD for primary (244
[91.4%]) or secondary (23 [8.6%]) prevention of SCD. Fifty-
three patients (5.2%) died (SCD, 30 [56.6%]; heart failure, 9
[17.0%], heart failure related, 6 [11.3%]; other cardiovascular
related, 3 [5.7%]; non–cardiovascular related, 2 [3.8%]; and
unknown cause, 3 [5.7%]), with an annual mortality rate of
0.89 (95% CI, 0.68-1.16). Eighty-nine patients reached the SCD
or equivalent end point within 5 years (SCD, 39 [43.8%]; aborted
SCD, 16 [18.0%]; appropriate ICD discharge, 24 [27.0%]; and
hemodynamically compromising, sustained VT, 10 [11.2%]),
with an annual SCD end point rate of 1.49 (95% CI, 1.15-1.92)
(eFigure 2B in the Supplement). Baseline clinical characteris-
tics of patients with and without SCD or SCD equivalent end
point and results from univariable regression analyses are
reported in Table 3. NYHA class 2 or higher, unexplained syn-
cope, nonsustained VT (NSVT), maximal wall thickness (MWT),
and left atrium (LA) diameter were associated with SCD at the
5% significance level.
Model Development
The risk model was developed using the entire follow-up data
and all events that occurred during the follow-up (ie, 1029 pa-
tients with 89 events.) A risk model was developed using the
preselected variables (unexplained syncope, NSVT, LA diam-
eter z score, MWT z score, and left-ventricular outflow tract
[LVOT] gradient); the estimates of hazard ratios for the result-
ing model are reported in Table 4. Missing data for the prese-
lected variables are summarized in eTable 4 in the Supple-
ment. Complete data were available for 527 patients (51.5%);
at least 1 predictor variable was missing in 48.5% of the sample.
Including NYHA classification (the only additional predictor
of missingness) as a predictor variable had little association with
the estimates of the hazard ratios. The risk of SCD at 5 years
for an individual patient with HCM can be calculated from the
following equation as demonstrated in the HCM Risk-Kids
calculator using Excel (Microsoft Corp) (depicted in the eAp-
pendix in the Supplement).
P(SCD at 5 years) = 1 − 0.949437808exp(prognostic index),
where prognostic index = 0.2171364 • (MWT z score – 11.09) –
0.0047562 • (MWT z score2 – 174.12) + 0.130365 • (LA diam-
eter z score – 1.92) + 0.429624 • unexplained syncope +
0.1861694 • NSVT – 0.0065555 • (maximal LVOT gradient –
21.8).
Validation
The performance of the model for predicting risk at 5 years was
assessed using 1029 patients with 58 events. The C index was
0.69 (95% CI, 0.66-0.72) and calibration slope was 0.98 (95%
CI, 0.59-1.38). Figure, B shows the comparison between the ob-
served and predicted 5-year risk of SCD by clinical risk groups
for 1 randomly selected imputed data set.
Clinical Implications
The clinical implications of the model were examined in 527
patients with 34 SCD end points who had complete data to al-
low calculation of 5-year SCD risk. The SCD end point was
reached by 3 patients (1.7%) with a predicted risk lower than
4% (n = 178), 5 patients (5%) with a predicted risk of 4% to less
than 6% (n = 100), and 26 patients (10.4%) with a predicted
risk of 6% or greater (n = 249) (Figure, A). Using a 5-year SCD
risk of 6% or greater to recommend primary prevention with
ICD implantation would identify 26 of 34 SCD end points
(76.5%), with ICD implantation in 223 of 493 patients (45.2%)
not reaching SCD end points within 5 years. Using a 5-year SCD
risk of 4% or greater to recommend primary prevention ICD
implantation would identify 31 of 34 SCD end points (91.2%),
with ICD implantation in 318 of 493 patients (64.5%) not reach-
ing SCD end points within 5 years.
The pediatric model was developed using preselected vari-
ables to predict the risk of SCD. The model’s ability to predict
risk at 5 years was validated; the C statistic was 0.69 (95% CI,
Table 2. Baseline Clinical Characteristicsa
Baseline Clinical Characteristic No. (%)
Age, median (IQR), y 11 (7-14)
Male sex 699 (68.3)
Family history
HCM (n = 1006) 534 (53.1)
SCD (n = 1020) 130 (12.8)
Unexplained syncope (n = 1023) 102 (9.9)
NYHA/Ross classification (n = 1006)
1 783 (77.8)
2 191 (19)
3 29 (2.9)
4 3 (0.3)
Medical therapy at baseline (n = 1021)
None 596 (58.4)
β-Blockers 410 (40.2)
Amiodarone 9 (0.9)
Other 6 (0.6)
NSVT on ambulatory ECG (n = 856) 55 (6.4)
MWT, mm
No. 997
Mean (SD) 17.1 (7.4)
z Score MWT
No. 906
Mean (SD) 11.1 (7.1)
LA diameter, mm
No. 712
Mean (SD) 33.4 (8.5)
z Score LA diameter
No. 675
Mean (SD) 1.9 (2.3)
LVOTg, max
No. 871
Median (IQR) 9 (6-22)
Abbreviations: ECG, electrocardiogram; HCM, hypertrophic cardiomyopathy;
IQR, interquartile range; LA, left atrium; LVOTg max, maximal left-ventricular
outflow tract gradient; MWT, maximal wall thickness; NSVT, nonsustained
ventricular tachycardia; NYHA, New York Heart Association; SCD, sudden
cardiac death.
a Total of 1024 patients unless otherwise indicated.
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0.66-0.72), and the calibration slope was 0.98 (95%, CI 0.59-
1.38). For every 10 ICDs implanted in patients with 6% or more
of a 5-year SCD risk, 1 patient may potentially be saved from
SCD at 5 years.
Comparison With Adult Risk Stratification Tool
The performance of the pediatric model to predict 5-year
risk of SCD was compared with that of the adult risk stratifi-
cation tool (HCM-Risk SCD). The adult model has modest
discriminatory ability (C index, 0.67; 95% CI, 0.65-0.69) but
does not predict risk accurately (calibration slope, 0.79; 95%
CI, 0.43-1.15) for the pediatric cohort. It seems the risk of
SCD is underestimated for all risk groups (eFigure 3 in the
Supplement). Including age and family history of SCD in the
pediatric model did not improve its performance (eTable 5
in the Supplement).
Discussion
To our knowledge, the model presented herein represents
the first validated approach to risk stratification in childhood
HCM and suggests that systematic risk evaluation can be
used to guide ICD implantation in young patients with the
disease. Compared with the prevalence in adults, HCM is a
relatively uncommon disease in childhood and has a more
diverse cause.1,35 Nevertheless, outside of infancy, the dis-
ease is caused mostly by mutations in sarcomere protein
genes36,37 and results in SCD in a significant minority of
children.3,38 Current approaches to risk stratification in
childhood HCM have remained largely unchanged for more
than 2 decades, with reliance on the assessment of a small
number of clinical features (risk factors) to guide treatment
Table 3. Clinical Characteristics of Patients With and Without Sudden Cardiac Death End Points
and Univariable Cox Proportional Hazards Regression Models
Characteristic
No. (%)
Hazard Ratio
(95% CI) P Value
Whole Cohort
(N = 1024)
Patients With SCD
End Points (n = 89)
Patients Without SCD
End Points (n = 938)
Age, median (IQR) 11 (7-14) 10 (6-13) 11 (7-14) 1.05 (1.00-1.11) .06
Male sex 699 (68.3) 65 (73) 634 (67.8) 0.73 (0.50-1.17) .20
NYHA class >1 223 (22.2) 28 (31.8) 195 (21.2) 1.70 (1.08-2.65) .02
Family history
SCD 130 (12.8) 12 (13.5) 118 (12.7) 1.01 (0.55-1.85) .98
HCM 534 (53.1) 42 (48.3) 492 (53.5) 0.83 (0.55-1.27) .39
Unexplained syncope 102 (9.9) 16 (18) 86 (9.2) 2.06 (1.20-3.54) .009
NSVT 55 (6.4) 12 (16.4) 43 (5.5) 1.93 (1.03-3.61) .04
MWT, mean (SD), mm 17.1 (7.4) 20 (7.5) 16.9 (7.3) 1.05 (1.02-1.07) <.001
z Score MWT, mean (SD) 11.1 (7.1) 15 (7.5) 10.7 (7) 1.05 (1.02-1.08) <.001
MWT ≥30 mm 81 (7.9) 25 (31.7) 164 (20.7) 2.35 (1.33-4.18) .004
LA diameter, mean (SD), mm 33.4 (8.5) 36.5 (9.3) 33 (8.3) 1.05 (1.02-1.08) .001
z Score LA diameter, mean (SD) 1.9 (2.3) 3.2 (2.6) 1.8 (2.2) 1.19 (1.08-1.30) <.001
LVOTg max, median (IQR), mm Hg 9 (6-22) 12 (6-36) 9 (6-20) 1.00 (0.99-1.01) .83
LVOT ≥30 mm Hg 189 (18.4) 25 (31.7) 164 (20.7) 1.48 (0.92-2.38) .11
Abbreviations: HCM, hypertrophic cardiomyopathy; LA, left atrium; IQR, interquartile range; LVOTg max, maximal left-ventricular outflow tract gradient;
MWT, maximal wall thickness; NSVT, nonsustained ventricular tachycardia; NYHA, New York Heart Association; SCD, sudden cardiac death.
Table 4. Pediatric Sudden Cardiac Death Risk Prediction Model and Sensitivity Analyses
for Predictor of Missingness
Predictor Variable
SCD Risk Prediction Model
Sensitivity Analysis:
Model Including Predictors of Missingness
Hazard Ratio (95% CI) P Value Hazard Ratio (95% CI) P Value
NSVT 1.20 (0.53-2.76) .66 1.16 (0.52-2.61) .72
LA diameter z score 1.14 (1.03-1.26) .01 1.13 (1.03-1.25) .01
MWT
z Score 1.24 (1.07-1.45) .005 1.24 (1.07-1.44) .005
z Score2 0.995 (0.99-1.00) .04 0.995 (0.99-1.00) .04
LVOT gradient 0.99 (0.99-1.00) .10 0.99 (0.99-1.00) .11
Unexplained syncope 1.54 (0.79-2.98) .20 1.52 (0.79-2.92) .22
NYHA 1.15 (0.62-2.11) .66
Uno C statistic 0.69 (0.66-0.72) NA 0.69 (0.66-0.72) NA
Calibration slope 0.98 (0.59-1.38) NA 0.96 (0.56-1.36) NA
Abbreviations: LA, left atrium;
LVOT, left ventricular outflow tract;
MWT, maximal wall thickness;
NA, not applicable;
NSVT, nonsustained ventricular
tachycardia; NYHA, New York
Heart Association; SCD, sudden
cardiac death.
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decisions.4,5 A recent validation study of this approach to
risk stratification has shown it to have limited discrimina-
tory power (C index statistic, 0.62) with a positive predictive
value of only 19%.6 In adults with HCM, there has been a
shift toward quantitative risk prediction based on tools, such
as HCM Risk-SCD,8 that form the basis of recommendations
for ICD therapy based on absolute thresholds of risk. How-
ever, the HCM Risk-SCD tool is not recommended for use in
childhood as patients younger than 16 years were specifi-
cally excluded in its development and echocardiographic
variables were not corrected for body surface area, which led
us to develop a new, pediatric-specific risk model. This study
shows that, if applied to children, the existing adult model
may underestimate the incidence of SCD for all risk groups
and has a limited discriminatory power.
The new pediatric model that we have developed shows
better discrimination between high- and low-risk patients with
good calibration between the expected and observed risk. The
performance is similar to that reported in adult cohorts for the
adult model.11 Predictor variables were included only if pre-
viously associated with SCD in published studies with the re-
sult that family history of SCD and age at presentation were
excluded. The lack of evidence in current literature support-
ing family history of SCD could be explained by a higher preva-
lence of de novo mutations in childhood, incomplete report-
ing of family history, or failure to adjust for family linkage.
Although presentation of HCM in young adulthood has been
linked with adverse outcomes,39 age was not included as a pre-
dictor variable as, outside of infancy,1 its role in prognosis re-
mains unclear. In keeping with this rationale, including both
age and family history of SCD as predictor variables did not im-
prove the model’s performance. The effect of age may have
been mitigated in the model by the fact that somatic growth
in childhood was accounted for by using body surface area–
corrected rather than absolute 2-dimensional echocardio-
graphic measurements. Although 2 previous studies re-
ported an increased risk of SCD in the presence of heart failure
symptoms,40,41 inclusion of this variable did not improve the
model’s performance.
To our knowledge, this study represents the largest popu-
lation of childhood HCM with nonsyndromic disease pub-
lished to date. The baseline demographics were similar to those
seen in previous population-based studies1,2,35,40 with the ex-
ception of familial disease, which was more prevalent than pre-
viously reported in registry studies although in keeping with
reports from reference centers.36 This higher prevalence of
familial disease may be explained by the exclusion of syn-
dromic disease (eg, RASopathy, inborn errors of metabolism,
or Friedreich ataxia) or by family screening as the indication
for initial evaluation but could also suggest that familial dis-
ease presenting during childhood is more common than usu-
ally appreciated. Compared with similar-sized adult cohorts,
there was a lower prevalence of traditional risk factors (eg, fam-
ily history of SCD, NSVT) yet a higher incidence of arrhythmic
events (1.49% vs 0.6%11). In addition, risk factors with signifi-
cant evidence in adult practice, such as family history of SCD
and LVOT gradient, were not associated with arrhythmic events
on univariable analysis in this cohort. The LVOT gradient ap-
pears to be inversely associated with the risk of SCD in this
population. The finding that LVOT obstruction may be pro-
tective is in agreement with another recent, large pediatric
population series but needs further exploration.42 Unex-
plained syncope, degree of hypertrophy, LA diameter, and
NSVT showed the strongest association with the study out-
come, although this finding was not significant at the 15% level
for NSVT. These findings are in agreement with a recent
meta-analysis19 and suggest that risk factors for SCD may dif-
fer between adult and pediatric cohorts.
Figure. Performance of the HCM Risk-Kids Model
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A, Kaplan-Meier curve showing cumulative probability of sudden cardiac death
(SCD) end points within 5 years of baseline evaluation by clinical risk groups
calculated by the pediatric SCD risk model. Patients with complete data for the
calculation of 5-year SCD risk estimates (n = 527) were classified into 3 risk
groups (<4%, 4%-<6%, and 6%). B, Comparison of observed and predicted
risk by clinical risk group of the pediatric SCD risk model (for 1 imputed data set).
Vertical bars represent observed (dark blue) and model-based predicted (light
blue) probability of SCD by 5 years. HCM indicates hypertrophic
cardiomyopathy.
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The complete case analysis suggests that the model iden-
tifies the majority of patients at risk of an SCD event during the
follow-up period. The identification of patients at risk of SCD
was at the expense of ICD implantation in 45% of patients not
yet reaching the end point during follow-up. However, as pre-
vious studies have demonstrated variable latency between ICD
implantation and first appropriate therapy,43 these young pa-
tients may yet benefit from the decision to implant a device.
Further refinement of the model presented could be achieved
by exploring the role of novel risk factors for SCD in child-
hood HCM, including genetic data, late gadolinium enhance-
ment on cardiac magnetic resonance imaging,44 and the rest-
ing 12-lead electrocardiogram, which, in a single study,45 has
been suggested to accurately predict the risk of SCD.
In addition, because childhood is a time of significant so-
matic growth, the phenotype of a patient may evolve rapidly
with a resulting change in the arrhythmic risk profile. Future
studies exploring the changing role of individual clinical risk
factors during childhood and use of serial clinical investiga-
tions in predicting risk would be valuable.
Limitations
Because childhood HCM is a rare disease and SCD is an un-
common event, a multicenter, retrospective, longitudinal de-
sign was necessary to develop a pediatric-specific model. This
study is therefore limited by inherent problems of retrospec-
tive studies, in particular, missing data. The higher propor-
tion of patients with at least 1 missing predictor compared with
the adult development cohort (48.5% in the present study vs
21.7%8) may be explained by difficulties obtaining certain in-
vestigations in young patients (eg, ambulatory electrocardio-
gram) and the use of contemporaneously written echocardio-
graphic reports.
Because missing data were associated with milder
hypertrophy and the absence of heart failure symptoms, the
complete case analysis is inherently biased toward those
with more severe disease. This bias may explain the pre-
dominance of patients with a calculated 5-year risk score of
4% or greater (n = 349/527). This bias also suggests that clini-
cians are more likely to investigate thoroughly in the pres-
ence of severe disease.
Because the cohort was recruited longitudinally, the length
of follow-up for individual patients varied, with a median
length of follow-up of 5.3 years. The longevity of an ICD de-
vice is reported to be between 5 and 9 years,46,47 although chil-
dren are known to be at increased risk for lead-related com-
plications necessitating revision.14,43 The finite battery life and
need for repeated device replacements, along with the life-
time burden of complications, needs to be carefully consid-
ered by clinicians when counseling patients and their parents
on ICD implantation.
Although this study includes data collected across a wide
time period, medical management of children with HCM has
not changed significantly over this time, and studies have pre-
viously shown no era effect on survival.3 However, patients
presenting in the earliest era (pre-1990) were more likely to be
symptomatic for heart failure symptoms and have NSVT de-
tected. Patients presenting in more recent years had lower ab-
solute MWT and corresponding z score, but this difference did
not reach statistical significance. The difference in MWT and
corresponding z score may be the result of patients being di-
agnosed at an earlier time point in disease expression, possi-
bly through family screening, although not at a younger age.
Inherent to the study design, a survival bias may exist for all
eras, as patients not surviving an out-of-hospital arrest are not
represented. Future studies comparing those surviving an out-
of-hospital arrest with those identified postmortem would be
useful but was beyond the scope of this study.
The model should be used only in patients with similar
clinical characteristics to the study cohort. In particular, it
should not be used in patients presenting in infancy or with
syndromic disease, inborn errors of metabolism, or neuro-
muscular disease.3,48 Future studies exploring the risk of SCD
in these subgroups are required.
The number of patients undergoing invasive treatment of
LVOT obstruction in this cohort was too small to model its as-
sociation with SCD risk. However, obstructive disease was
uncommon in this cohort, with only 18% having a gradient
above 30 mm Hg.
Conclusions
We present what we believe to be the first validated risk strati-
fication model for SCD in childhood HCM developed from a
large, international cohort using readily collected data on clini-
cal risk factors. The individualized estimates of risk could help
clinicians to identify patients at highest risk and balance the
risk of an arrhythmic event with prophylactic ICD implanta-
tion in conjunction with the patient and their parents or guard-
ians. External validation studies are now required to demon-
strate the accuracy of this model’s predictions in diverse patient
populations. Consensus opinion of experts will be required to
determine whether absolute thresholds for ICD recommen-
dations are needed and, if so, where those thresholds should
be set. Further refinement of this model could be achieved by
including novel clinical risk predictors, such as cardiac mag-
netic resonance imaging and genetic data.
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